Tailwinds' Take: Anixa continues to demonstrate nothing but very positive results, so expect more from this presentation. We continue to believe the risk / reward of ANIX is very compelling as data continues to be positive on both products...
In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December. These are important events as the FDA will review data submitted before even agreeing to...
Tailwinds' Take: very positive development getting Cchek in front of the FDA for preliminary discussions, especially how quickly the meeting was accepted. With two programs on track, ANIX is very undervalued by the markets. SAN JOSE, Calif., Oct. 24, 2018...
Tailwinds' Take: although this is a minor delay from previous (best case) guidance, it is still fabulous news that Anixa expects to have a CAR-T drug in humans next summer. We expect to see the stock at much higher...
Tailwinds' Take: This is outstanding data. The detection of cancer remains in line with prior releases, but the ability to detect benign versus malignant is huge! Almost 80% of biopsies are unnecessary. Removing over 50% of these will be...
Tailwinds' Take: with two products approaching FDA submissions for clinical trials, ANIX is positioned for significant catalysts and value generation over the next few months. SAN JOSE, Calif., Oct. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company...
Tailwinds' Take: this group of SAB members includes scientists who are working on Anixa's CAR-T therapy, which is a major endorsement of the product and platform. This is a very distinguished team and includes some of the world's top...
Tailwinds' Take: this is an indication that the company could have potentially huge news soon on differentiating between benign and malignant tumors. As Dr. Kumar says, "Our recent Cchek™ data demonstrates that many of these unneeded biopsies may be...
SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its...
We got the chance to speak with Dr. Amit Kumar, the CEO of ITUS Corp. this last week. Having heard little about the progress of Cchek of late, and knowing that their CAR-T drug is going to be presented...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.